ABBOTT PARK, Ill., May 21 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion, plus $400 million annually for the next four years, giving Abbott the No.

Piramal Healthcare, a part of the Piramal Group, has completed a definitive agreement with Germany-based PlasmaSelect to acquire its polygeline-based blood plasma products marketed under the brand name 'Haemaccel' in over 38 countries.